Target intelligence / Profile preview

Feline panleukopenia virus capsid protein VP2 (FPV VP2) (FPV VP2)

Target
FPV VP2
Molecular classification
Viral capsid protein, Structural protein, Receptor-binding protein
01

Overview

The Feline panleukopenia virus (FPV) VP2 protein is the major structural component of the viral capsid, comprising approximately 90% of the 60-subunit icosahedral shell (UniProt: P03304). It is essential for the viral infection process, as it directly binds to the feline transferrin receptor (TfR) to facilitate cell entry via receptor-mediated endocytosis (PubMed: 12767992). Mutations within the VP2 protein are primarily responsible for determining the host range of the virus, allowing it to adapt to different feline and canine species (PubMed: 21183405). Because it is exposed on the viral surface, VP2 is the primary target for neutralizing antibodies produced by the host's immune system during infection or following vaccination. Most commercial vaccines for feline panleukopenia utilize the VP2 protein, either in inactivated or modified-live virus forms, to induce protective immunity. In diagnostics, VP2 is the target for various assays, including enzyme-linked immunosorbent assays (ELISA) and polymerase chain reaction (PCR) tests used to detect the virus in clinical samples. Research into therapeutic interventions often focuses on blocking the interaction between VP2 and the host transferrin receptor to prevent viral spread. Understanding the structural biology of VP2 is crucial for monitoring the evolution of parvoviruses and ensuring the continued efficacy of feline vaccination programs.

Other names
Major capsid protein VP2Capsid protein 2FPV VP2 proteinVP2 structural protein
02

Mechanism of action

Neutralization of viral particles by binding to the VP2 capsid protein, thereby preventing the virus from attaching to the host transferrin receptor and inhibiting subsequent cellular entry and replication.

03

Biological functions

Viral entryHost cell receptor bindingCapsid assemblyHost range determinationIntracellular trafficking
04

Disease associations

Feline panleukopeniaInfectionFeline infectious enteritis
05

Safety considerations

Antigenic drift leading to vaccine escapePotential for vaccine-associated adverse events in felinesCross-species transmission potentialIncomplete neutralization
06

Interacting drugs

Feline panleukopenia vaccine (modified live)

3 more in the full profile.

07

Biomarkers

Anti-VP2 antibody titerFecal VP2 antigenVP2-specific PCRHemagglutination inhibition (HI) titer

Beyond the preview

Go deeper on Feline panleukopenia virus capsid protein VP2 (FPV VP2) (FPV VP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Feline panleukopenia virus capsid protein VP2 (FPV VP2) (FPV VP2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call